Shufang Liang

机构：Sichuan University, China Tobacco, Aerospace Center Hospital, State Key Laboratory of Biotherapy, Renmin University of China

发表论文 105 篇 · 总被引 3562 次 · h-index 36

代表论文

• Targeting tumor-associated macrophages for cancer treatment (2022 · Cell & Bioscience · 被引 219)
• PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis (2022 · Cell Death and Disease · 被引 92)
• Prognostic value of inflammatory markers NLR, PLR, LMR, dNLR, ANC in melanoma patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review (2024 · Frontiers in Immunology · 被引 46)
• DCLK1 autoinhibition and activation in tumorigenesis (2021 · The Innovation · 被引 38)
• SUMOylation of AnxA6 facilitates EGFR-PKCα complex formation to suppress epithelial cancer growth (2023 · Cell Communication and Signaling · 被引 25)
• Novel inhibitors targeting the PGK1 metabolic enzyme in glycolysis exhibit effective antitumor activity against kidney renal clear cell carcinoma in vitro and in vivo (2024 · European Journal of Medicinal Chemistry · 被引 19)